A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 and 400 mcg o.d.) in patients with chronic obstructive pulmonary disease using formoterol (12 mcg b.i.d.) as an active control.
Latest Information Update: 27 Jul 2020
At a glance
- Drugs Indacaterol (Primary) ; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis
Most Recent Events
- 26 Jul 2020 Status changed from recruiting to completed.
- 23 May 2011 This trial is recruiting in Great Britain and has completed in Germany and discontinued in Sweden.
- 17 May 2011 New trial record